Healthcare Swedish Community

1. The Narrative: The High Tech Precision Play The narrative for RaySearch is that of a highly specialized software leader in the oncology market.Read more

EQL Pharma is pushing hard to expand its range of everyday medicines, with a growing lineup of new products that could keep sales climbing fast. The catch is that the shares already reflect a lot of optimism, and execution plus cash flow need to keep up for the story to work.Read more

A small Swedish biotech is trying to make medicines work better and last longer in the body by wrapping them in a protective “shell.” The big question is whether this delivery tech can attract major partners and turn early promise into real products—before setbacks or slow adoption get in the way.Read more

Dedicare supplies health and social care staff in a region where ageing populations and ongoing staff shortages keep demand strong. The catch is that tougher rules and fiercer rivals are squeezing results, and the story hinges on whether Dedicare can defend its position while expanding into new markets.Read more

Surgical Science Sweden benefits from the growing shift toward digital and simulation-based training for surgeons, but its sales can swing sharply as hospitals and big robot-surgery partners buy in batches and on delayed budgets. Heavy spending on new products and acquisitions could pay off later, yet pricing pressure and slower-than-hoped integration may keep profits under strain in the meantime.Read more

RaySearch sells software that helps hospitals plan and manage cancer treatment, and growing demand plus smarter, more connected tools could make it a bigger part of how clinics run oncology care. But the upside hinges on smooth customer upgrades and staying ahead of tougher rules and stronger competition.Read more

RaySearch is trying to grow from its core radiotherapy software into a wider set of cancer treatments, but that bigger ambition could also slow rollouts and make adoption harder for clinics. The story hinges on whether today’s upgrade-driven sales and rising interest in its newer platforms turn into steady, durable growth—or fade once the current replacement wave ends.Read more

Getinge is leaning into organ transport, digital tools, and service-style offerings that could make its profits grow faster than most people expect, especially as rivals pull back in critical care equipment. But trade costs, tougher regulators, and the risk that hospitals shift spending away from big hardware purchases could slow the story down.Read more

Mentice is pushing into portable training simulators, but cheaper, easier-to-copy tools could turn its hardware into a price fight and slow long-term growth. Add in customers building more training in-house and the need for ongoing heavy product development, and the business may struggle to turn today’s momentum into lasting profits.Read more